{"id":655470,"date":"2023-06-14T08:44:02","date_gmt":"2023-06-14T08:44:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=655470"},"modified":"2023-06-14T08:44:02","modified_gmt":"2023-06-14T08:44:02","slug":"icosnext-generation-immunotherapy-market-report-2035-market-size-treatment-therapies-fda-approval-and-companies-by-delveinsight-glaxosmithkline-bristolmyers-squibb-jounce-therapeutic-xencor","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/icosnext-generation-immunotherapy-market-report-2035-market-size-treatment-therapies-fda-approval-and-companies-by-delveinsight-glaxosmithkline-bristolmyers-squibb-jounce-therapeutic-xencor_655470.html","title":{"rendered":"ICOS-Next Generation Immunotherapy Market Report 2035: Market Size, Treatment Therapies, FDA Approval, and Companies by DelveInsight | GlaxoSmithKline, Bristol-Myers Squibb, Jounce Therapeutic, Xencor"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1686662121.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"ICOS-Next Generation Immunotherapy Market Report 2035: Market Size, Treatment Therapies, FDA Approval, and Companies by DelveInsight | GlaxoSmithKline, Bristol-Myers Squibb, Jounce Therapeutic, Xencor\" src=\"https:\/\/www.abnewswire.com\/uploads\/1686662121.jpeg\" alt=\"ICOS-Next Generation Immunotherapy Market Report 2035: Market Size, Treatment Therapies, FDA Approval, and Companies by DelveInsight | GlaxoSmithKline, Bristol-Myers Squibb, Jounce Therapeutic, Xencor\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>ICOS-Next Generation Immunotherapy Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\">(New York, USA) DelveInsight&rsquo;s &lsquo;<strong>ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast&ndash;2035<\/strong>&rsquo; report delivers an in-depth understanding of the ICOS as well as the market trends of ICOS-Next Generation Immunotherapy in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the ICOS-Next Generation Immunotherapy report, click here @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>ICOS-Next Generation Immunotherapy Competitive Landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some facts of ICOS-Next Generation Immunotherapy competitive report are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The ICOS-Next Generation Immunotherapy market size is expected to reach USD 8,676 Million by 2035.<\/li>\n<li>The major ICOS-Next Generation Immunotherapy companies such as GlaxoSmithKline, Bristol-Myers Squibb, Jounce Therapeutics, Xencor, Kymab, etc, and others will significantly increase the ICOS-Next Generation Immunotherapy market during the forecast period (2022&ndash;2035).&nbsp;&nbsp;<\/li>\n<li>The expected launch of ICOS-Next Generation Immunotherapy emerging therapies, such as GSK3359609, Vopratelimab, KY1044, BMS-986226, XmAb23104, and other treatments, would lead to a significant increase in the ICOS-Next Generation Immunotherapy market size during the forecast period (2022&ndash;2035).<\/li>\n<li>According to Delveinsight&rsquo;s analysis, the market is expected to show positive growth due to the launch of potential upcoming therapies in the ICOS target during the forecast period (2022&ndash;2035). Moreover, the US occupies approximately 49.48% market share of ICOS in the overall market size of the 7MM in 2035.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about the ICOS-Next Generation Immunotherapy Epidemiology and treatment landscape, click here @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>ICOS-Next Generation Immunotherapy Market Forecast<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ICOS-Next Generation Immunotherapy Overview:<\/strong><\/p>\n<p style=\"text-align: justify;\">Cancer immunotherapy (CI) is rapidly advancing and can now be considered to be the &ldquo;fifth pillar&rdquo; of cancer therapy, joining the ranks of surgery, cytotoxic chemotherapy, radiation, and targeted therapy. The CI which has sparked the most interest involves antibodies to inhibitory immune checkpoint molecules.<\/p>\n<p style=\"text-align: justify;\">Inducible co-stimulator (ICOS) is a specific T cell co-stimulatory molecule of the CD28\/CTLA-4 family mainly expressed by CD4 T cells. It is a co-stimulator of proliferation and cytokine production by these cells. Its levels are upregulated in activated T lymphocytes, especially after the use of anti-CTLA4 therapies, and its expression is considered as a biomarker to indicate that anti-CTLA4 agents are binding its target.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free sample report @&nbsp;<\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the ICOS-Next Generation Immunotherapy market report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of ICOS-Next Generation Immunotherapy, explaining its pathophysiology, and current trends in the research.<\/li>\n<li>Additionally, an all-inclusive account of emerging therapies for ICOS-Next Generation Immunotherapy is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/li>\n<li>A detailed review of ICOS-Next Generation Immunotherapy market; historical and forecasted is included in the report, covering drug outreach in the 7MM.<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the ICOS-Next Generation Immunotherapy market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free sample report @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>ICOS-Next Generation Immunotherapy Emerging Drugs<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>GSK3359609: GlaxoSmithKline<\/strong><\/p>\n<p style=\"text-align: justify;\">GSK3359609, an inducible T cell co-stimulatory (ICOS) agonist antibody is designed to selectively enhance T cell function. After the administration, anti-ICOS agonist antibody GSK3359609 targets and binds to ICOS expressed on tumor-infiltrating CD4-positive T cells. This stimulates ICOS-positive T-cell proliferation which enhances cytotoxic T-lymphocyte (CTL) survival and increases CTL-mediated immune responses against tumor cells. ICOS, a T-cell specific, CD28-superfamily costimulatory molecule, and immune checkpoint protein is normally expressed on certain activated T cells and plays a key role in the proliferation and activation of T cells.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vopratelimab: Jounce Therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">Vopratelimab (also known as JTX-2011) is a clinical-stage monoclonal antibody that binds and activates ICOS, the Inducible T cell CO-Stimulator which is a protein present on the surface of certain T cells found in many solid tumors. The drug is currently in phase II (EMERGE) clinical trial in combination with ipilimumab in patients previously treated with PD-1\/PD-L1 inhibitor therapies. The product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates ICOS, a protein on the surface of certain T cells commonly found in many solid tumors.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for a free sample report @ <\/strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=apr\"><strong>https:\/\/www.delveinsight.com\/sample-request\/icos-next-generation-immunotherapy-competitive-landscape<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. Competitive Intensity of ICOS-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">4. Market Competition of ICOS-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">5. Technological innovations in ICOS-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">6. Multivariate analysis of the key players in ICOS-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">7. ICOS-Next Generation Immunotherapy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">7.1. Market Share (%) Distribution of Next-Generation Immunotherapy in 2035<\/p>\n<p style=\"text-align: justify;\">8. Pipeline Therapeutics Analysis (Active Products)<\/p>\n<p style=\"text-align: justify;\">9. Overview: Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">10. Future Prospects and Challenges in ICOS-Next Generation Immunotherapy<\/p>\n<p style=\"text-align: justify;\">10.1. Current Clinical Challenges in Immunotherapies<\/p>\n<p style=\"text-align: justify;\">10.2. Future direction of improving response rates of Immunotherapy<\/p>\n<p style=\"text-align: justify;\">11. SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">12. ICOS-Next Generation Immunotherapy Epidemiology and Forecasting Assumptions<\/p>\n<p style=\"text-align: justify;\">13. Emerging ICOS-Next Generation Immunotherapy Drugs<\/p>\n<p style=\"text-align: justify;\">13.2. GSK3359609: GlaxoSmithKline<\/p>\n<p style=\"text-align: justify;\">13.3. Vopratelimab (JTX-2011): Jounce Therapeutics<\/p>\n<p style=\"text-align: justify;\">13.4. KY1044: Kymab<\/p>\n<p style=\"text-align: justify;\">13.5. BMS-986226 (Anti-ICOS): Bristol-Myers Squibb<\/p>\n<p style=\"text-align: justify;\">13.6. XmAb23104: Xencor<\/p>\n<p style=\"text-align: justify;\">14. Assessment by Indication Type<\/p>\n<p style=\"text-align: justify;\">15. Assessment by Route of Administration<\/p>\n<p style=\"text-align: justify;\">16. ICOS-7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">17. ICOS-Next Generation Immunotherapy Market Drivers<\/p>\n<p style=\"text-align: justify;\">18. ICOS-Next Generation Immunotherapy Market Barriers<\/p>\n<p style=\"text-align: justify;\">19. Appendix<\/p>\n<p style=\"text-align: justify;\">19.1. Report Methodology<\/p>\n<p style=\"text-align: justify;\">20. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">21. Disclaimer<\/p>\n<p style=\"text-align: justify;\">22. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About DelveInsight<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=icosnext-generation-immunotherapy-market-report-2035-market-size-treatment-therapies-fda-approval-and-companies-by-delveinsight-glaxosmithkline-bristolmyers-squibb-jounce-therapeutic-xencor\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +19193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/consulting\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/consulting<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/consulting\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=icosnext-generation-immunotherapy-market-report-2035-market-size-treatment-therapies-fda-approval-and-companies-by-delveinsight-glaxosmithkline-bristolmyers-squibb-jounce-therapeutic-xencor\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ICOS-Next Generation Immunotherapy Market (New York, USA) DelveInsight&rsquo;s &lsquo;ICOS-Next Generation Immunotherapy Competitive Landscape and Market Forecast&ndash;2035&rsquo; report delivers an in-depth understanding of the ICOS as well as the market trends of ICOS-Next Generation Immunotherapy in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/icosnext-generation-immunotherapy-market-report-2035-market-size-treatment-therapies-fda-approval-and-companies-by-delveinsight-glaxosmithkline-bristolmyers-squibb-jounce-therapeutic-xencor_655470.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-655470","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=655470"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/655470\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=655470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=655470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=655470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}